Profound Medical (PROF) Corporate presentation summary

Strategic focus and product overview

• Emphasis on growing revenue with TULSA-PRO for prostate cancer and BPH, while advancing Sonalleve for gynecological and oncology indications through clinical trials and showcase sites in Europe and Asia.

• TULSA-PRO offers precision, incision-free ablation for prostate cancer and BPH, with a robotic system and AI-driven workflow enhancements.

• Sonalleve MR-HIFU system targets adenomyosis, uterine fibroids, and is being explored for pancreatic and other solid organ cancers.

Clinical evidence and competitive positioning

• Over 70 peer-reviewed publications and 200+ conference presentations support TULSA-PRO’s efficacy across a wide range of prostate indications, including whole-gland, partial, salvage, and hybrid cases.

• CAPTAIN trial demonstrates TULSA-PRO’s superior safety and non-inferior efficacy compared to radical prostatectomy, with significantly less blood loss, shorter hospital stays, and faster recovery.

• TULSA-PRO patients experience better preservation of urinary continence and erectile function at 6 months versus surgery.

• TULSA-PRO is positioned as more profitable for hospitals and urologists, with higher Medicare payments and lower operating costs compared to robotic prostatectomy.

Technology and innovation

• TULSA-PRO uses focused ultrasound energy for gentle, precise ablation, resulting in significant prostate volume reduction and minimal side effects.

• AI software modules enhance workflow, automate contouring, and optimize treatment plans for both prostate cancer and BPH, improving efficiency and safety.

• TULSA-PRO is compatible with a growing installed base of MRI systems, and partnerships with Siemens and Cook Medical are expanding interventional MRI adoption.